


IN THE CLAIMS:

Please amend claims 3-7 and 9, cancel claim 10 and add new claims 11-17, as follows:

1. (Original) A bisacyloxypropylcysteine conjugate according to formula (I),



where R_1 and R_2 can be identical or different and are fatty acid radicals which are bonded by way of the carboxyl group,

$Y = -NH-, -O-, -S-$ or $-OCO-$,

R_3 is a covalently, ionically or associatively bonded conjugate radical, in particular a water-soluble and physiologically tolerated, covalently or ionically bonded polymer, in particular covalently bonded polyethylene glycol (polyoxyethylene),

$-(CH_2-CH_2-O)_m-CH_2-CH_2-X$,


where $X = OR, NR_2, SR$ or $COOR$, and

$R = H$, benzyl- or C_{1-6} -alkyl, where several radicals R can be identical or different,

a polyoxyethylene-polyoxypropylene copolymer, a dextran, a sugar, a

polyvinylpyrrolidone, an alginate, a pectin or a collagen,

and where the polymeric radical R_3 is substituted once, twice or several times by



2. (Original) A bisacyloxypropylcysteine conjugate as claimed in claim 1, characterized in that the radicals $R_{1,2}$, which can be identical or different, are C_{7-25} , preferably C_{8-22} -alkyl, -alkenyl or -alkynyl groups, and the unsaturated positions are preferably in the cis configuration, with the alkyl, alkenyl and alkynyl radicals being branched or unbranched, cyclic or cycloalkyl-substituted radicals.
3. (Currently Amended) A bisacyloxypropylcysteine conjugate as claimed in claim 1 or 2, characterized in that the molecular weight of a water-soluble polymer radical is selected such that it amounts to from 100 to 30 000 daltons per conjugate molecule.
4. (Currently Amended) A bisacyloxypropylcysteine conjugate as claimed in ~~one of claims 1 to 3~~ claim 1, characterized in that the polyethylene glycol of the radical R_3 has a chain length m of from 5 to 700, preferably of from 100 to 500.
5. (Currently Amended) A bisacyloxypropylcysteine conjugate as claimed in ~~one of claims 1 to 4~~ claim 1, characterized in that the compound is a S-[2,3-bis(acyloxy)-(2S)-propyl]-L-cysteinylcarboxypolyethylene glycol, preferably S-[2,3-bis(palmitoyloxy)-(2s)-propyl]-L-cysteinylcarboxypolyethylene glycol.
6. (Currently Amended) A bisacyloxypropylcysteine conjugate as claimed in ~~one of claims 1 to 4~~ claim 1, characterized in that the compound is a S-[2,3-bis(acyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol, preferably S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinylcarboxypolyethylene glycol.
7. (Currently Amended) A pharmaceutical composition, comprising a bisacyloxypropylcysteine conjugate as claimed in ~~one of claims 1 to 6~~ claim 1.
8. (Original) The pharmaceutical composition as claimed in claim 7, characterized in that it comprises pharmaceutical additives or auxiliary substances and, preferably, a pharmaceutically tolerated excipient.

9. (Currently Amended) The pharmaceutical composition as claimed in claim 7 ~~or 8~~ in the form of a formulation which is suitable for injection, for inhalation or for intranasal or topical administration.

10. (Currently amended) The use of the bisacyloxypropylcysteine conjugates as claimed in ~~one of claims 1 to 6, or of the pharmaceutical composition as claimed in claim 7, 8 or 9;~~ claim 1 for stimulating macrophages, for stimulating antibody synthesis, for defense against infection, for immuno stimulation, for treatment in connection with ~~particularly in regard to~~ tumors, for preventing septic shock, for ~~and~~ treating septic shock, for wound healing, or for use ~~and~~ as an adjuvant for vaccines.